JP6912199B2 - 免疫腫瘍溶解療法 - Google Patents

免疫腫瘍溶解療法 Download PDF

Info

Publication number
JP6912199B2
JP6912199B2 JP2016536482A JP2016536482A JP6912199B2 JP 6912199 B2 JP6912199 B2 JP 6912199B2 JP 2016536482 A JP2016536482 A JP 2016536482A JP 2016536482 A JP2016536482 A JP 2016536482A JP 6912199 B2 JP6912199 B2 JP 6912199B2
Authority
JP
Japan
Prior art keywords
virus
deletion
tumor
trif
vaccinia virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016536482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527920A5 (enExample
JP2016527920A (ja
Inventor
ソーン，スティーブン，ハワード
Original Assignee
ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション
ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション, ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション filed Critical ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション
Publication of JP2016527920A publication Critical patent/JP2016527920A/ja
Publication of JP2016527920A5 publication Critical patent/JP2016527920A5/ja
Application granted granted Critical
Publication of JP6912199B2 publication Critical patent/JP6912199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2016536482A 2013-08-22 2014-08-22 免疫腫瘍溶解療法 Active JP6912199B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22
US61/868,978 2013-08-22
PCT/US2014/052308 WO2015027163A1 (en) 2013-08-22 2014-08-22 Immuno-oncolytic therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019133264A Division JP7021154B2 (ja) 2013-08-22 2019-07-19 免疫腫瘍溶解療法

Publications (3)

Publication Number Publication Date
JP2016527920A JP2016527920A (ja) 2016-09-15
JP2016527920A5 JP2016527920A5 (enExample) 2017-09-28
JP6912199B2 true JP6912199B2 (ja) 2021-08-04

Family

ID=52484194

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016536482A Active JP6912199B2 (ja) 2013-08-22 2014-08-22 免疫腫瘍溶解療法
JP2019133264A Active JP7021154B2 (ja) 2013-08-22 2019-07-19 免疫腫瘍溶解療法
JP2022015459A Active JP7333431B2 (ja) 2013-08-22 2022-02-03 免疫腫瘍溶解療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019133264A Active JP7021154B2 (ja) 2013-08-22 2019-07-19 免疫腫瘍溶解療法
JP2022015459A Active JP7333431B2 (ja) 2013-08-22 2022-02-03 免疫腫瘍溶解療法

Country Status (27)

Country Link
US (2) US11478518B2 (enExample)
EP (3) EP3778897B1 (enExample)
JP (3) JP6912199B2 (enExample)
KR (1) KR102389240B1 (enExample)
CN (1) CN105658795B (enExample)
AU (1) AU2014308648B2 (enExample)
CA (3) CA3213715A1 (enExample)
DK (2) DK3036329T3 (enExample)
EA (1) EA037582B1 (enExample)
ES (2) ES2971528T3 (enExample)
FI (1) FI3778897T3 (enExample)
HR (1) HRP20240078T1 (enExample)
HU (1) HUE066593T2 (enExample)
IL (1) IL243996A0 (enExample)
LT (1) LT3778897T (enExample)
MD (2) MD4624C1 (enExample)
MX (1) MX2016002257A (enExample)
NZ (1) NZ716825A (enExample)
PE (1) PE20160673A1 (enExample)
PH (1) PH12016500329A1 (enExample)
PL (1) PL3778897T3 (enExample)
PT (1) PT3778897T (enExample)
RS (1) RS65104B1 (enExample)
SG (1) SG11201600960PA (enExample)
SI (1) SI3778897T1 (enExample)
SM (1) SMT202400047T1 (enExample)
WO (1) WO2015027163A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022062171A (ja) * 2013-08-22 2022-04-19 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 免疫腫瘍溶解療法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510143A (ja) 2015-02-25 2018-04-12 メモリアル スローン ケタリング キャンサー センター 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10370647B2 (en) * 2015-07-22 2019-08-06 National University Corporation Tottori University Host regulatory factor that enhances replication and/or propagation of vaccinia virus
CA2996120C (en) * 2015-09-08 2024-02-20 Sillajen, Inc. Modified oncolytic vaccinia viruses expressing a cytokine and a carboxylesterase and methods of use thereof
JP2018532810A (ja) 2015-11-07 2018-11-08 マルチビア インコーポレイテッド がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物
BR112018016948A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
BR112018016949A2 (pt) 2016-02-25 2019-01-08 Memorial Sloan Kettering Cancer Center vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer
US12150969B2 (en) * 2016-03-25 2024-11-26 University of Pittsburgh—of the Commonwealth System of Higher Education Synthetically enveloped virus
EP3254692A1 (en) * 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
AU2017298385A1 (en) 2016-07-19 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting STAT3
KR20190059297A (ko) * 2016-09-21 2019-05-30 스티븐 에이치. 쏜 고-이동성 군 박스 1 돌연변이체
GB201616365D0 (en) 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
AU2018215558B2 (en) * 2017-02-03 2023-05-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
JP7206212B2 (ja) * 2017-03-06 2023-01-17 タラリス・セラピューティクス・インコーポレイテッド 治療用細胞組成物の効力を決定するための方法及び組成物
WO2018195552A1 (en) * 2017-04-21 2018-10-25 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN111556757A (zh) * 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
US11633441B2 (en) 2017-12-01 2023-04-25 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
JP7312412B2 (ja) 2018-01-05 2023-07-21 オタワ ホスピタル リサーチ インスティチュート 改変オルトポックスウイルスベクター
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
KR20210032495A (ko) * 2018-07-20 2021-03-24 안선 바이오파르마, 아이엔씨. 암 세포, 면역 세포 및 종양 미세환경에 시알리다제의 전달
WO2020056424A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
KR20210132003A (ko) * 2018-12-21 2021-11-03 오타와 하스피털 리서치 인스티튜트 변형된 오르토폭스 바이러스 벡터
KR20210113632A (ko) * 2019-01-07 2021-09-16 칼리버 임뮤노쎄라퓨틱스, 인크. 암을 치료하는 방법
TW202038994A (zh) * 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
EP3923967A1 (en) 2019-02-14 2021-12-22 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP7326663B2 (ja) * 2019-08-26 2023-08-16 バイオノックス インコーポレイテッド がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物
WO2021076982A1 (en) * 2019-10-16 2021-04-22 KaliVir Immunotherapeutics LLC Modified extracellular enveloped virus
EP4061417A4 (en) * 2019-11-20 2023-10-11 University of Pittsburgh - of the Commonwealth System of Higher Education VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
IL293627A (en) * 2019-12-12 2022-08-01 Ignite Immunotherapy Inc Variant oncolytic vaccinia virus and methods of use thereof
US20230201283A1 (en) * 2020-01-09 2023-06-29 Pfizer Inc. Recombinant vaccinia virus
CN115243714A (zh) * 2020-03-06 2022-10-25 匹兹堡大学联邦系统高等教育 用于治疗癌症的表达irf调节剂的溶瘤病毒
KR20230110545A (ko) 2020-11-19 2023-07-24 칼리버 임뮤노쎄라퓨틱스, 인크. 종양 미세환경 재형성에 의한 종양용해 면역요법
MX2023012608A (es) * 2021-04-30 2023-11-03 Kalivir Immunotherapeutics Inc Virus oncoliticos para la expresion modificada del mhc.
CA3224374A1 (en) * 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9305855A (es) 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad.
WO2000073479A1 (en) 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
CN101912421A (zh) * 2002-08-12 2010-12-15 杰能斯有限公司 涉及痘病毒和癌的方法及组合物
JPWO2007023725A1 (ja) * 2005-08-25 2009-02-26 公立大学法人横浜市立大学 遺伝子ワクチン
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US9180149B2 (en) * 2005-09-07 2015-11-10 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2009124044A2 (en) * 2008-03-31 2009-10-08 University Of Florida Research Foundation, Inc. Tumor growth inhibition via conditioning of tumor microenvironment
AU2010291901C1 (en) 2009-09-14 2016-03-03 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus combination cancer therapy
US20130202639A1 (en) 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
US11149254B2 (en) * 2011-04-15 2021-10-19 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
EP3778897B1 (en) 2013-08-22 2023-12-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Immuno-oncolytic therapies

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022062171A (ja) * 2013-08-22 2022-04-19 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 免疫腫瘍溶解療法
US11478518B2 (en) 2013-08-22 2022-10-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Immuno-oncolytic therapies
JP7333431B2 (ja) 2013-08-22 2023-08-24 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 免疫腫瘍溶解療法
US12514888B2 (en) 2013-08-22 2026-01-06 University of Pittsburgh—of the Commonwealth System of Higher Education Immuno-oncolytic therapies

Also Published As

Publication number Publication date
PT3778897T (pt) 2024-02-01
KR102389240B1 (ko) 2022-04-20
KR20160044529A (ko) 2016-04-25
EP3778897A1 (en) 2021-02-17
SG11201600960PA (en) 2016-03-30
CA2921041A1 (en) 2015-02-26
HRP20240078T1 (hr) 2024-03-29
HK1223402A1 (zh) 2017-07-28
CA3213715A1 (en) 2015-02-26
JP2022062171A (ja) 2022-04-19
DK3036329T3 (da) 2021-01-11
AU2014308648B2 (en) 2020-11-12
HUE066593T2 (hu) 2024-08-28
FI3778897T3 (fi) 2024-01-25
MD4748B1 (ro) 2021-02-28
EP4324918A3 (en) 2024-04-24
EP3036329A4 (en) 2017-08-02
NZ716825A (en) 2022-02-25
WO2015027163A1 (en) 2015-02-26
JP7021154B2 (ja) 2022-02-16
DK3778897T3 (da) 2024-01-29
EP3036329B1 (en) 2020-10-07
SI3778897T1 (sl) 2024-03-29
US20230008089A1 (en) 2023-01-12
PL3778897T3 (pl) 2024-04-02
US12514888B2 (en) 2026-01-06
EP3036329A1 (en) 2016-06-29
US11478518B2 (en) 2022-10-25
MD4624B1 (ro) 2019-03-31
EA037582B1 (ru) 2021-04-16
PH12016500329A1 (en) 2016-05-02
MD4624C1 (ro) 2019-10-31
MX2016002257A (es) 2016-11-08
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
CN105658795A (zh) 2016-06-08
CA2921041C (en) 2023-10-31
ES2971528T3 (es) 2024-06-05
EA201690444A1 (ru) 2016-08-31
US20160235793A1 (en) 2016-08-18
MD4748C1 (ro) 2021-09-30
CN105658795B (zh) 2020-07-03
PE20160673A1 (es) 2016-07-21
IL243996A0 (en) 2016-04-21
EP3778897B1 (en) 2023-12-20
AU2014308648A1 (en) 2016-03-03
JP2019205451A (ja) 2019-12-05
CA3213683A1 (en) 2015-02-26
ES2847305T3 (es) 2021-08-02
JP2016527920A (ja) 2016-09-15
EP4324918A2 (en) 2024-02-21
LT3778897T (lt) 2024-02-12
WO2015027163A9 (en) 2016-04-14
JP7333431B2 (ja) 2023-08-24
RS65104B1 (sr) 2024-02-29
SMT202400047T1 (it) 2024-03-13

Similar Documents

Publication Publication Date Title
JP7021154B2 (ja) 免疫腫瘍溶解療法
JP7025339B2 (ja) 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
JP7724601B2 (ja) 腫瘍溶解性ウイルス療法
AU2014308648A2 (en) Immuno-oncolytic therapies
BR112021012630A2 (pt) Poxvírus modificado, método para produzir o poxvírus modificado e composição
Jia et al. Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer
Jiang et al. Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors
Derani Combining radiation and oncolytic measles virus for the treatment of refractory tumors
US20220211814A1 (en) Il-36 cytokine expressing oncolytic viruses for treating cancer
HK40104741A (en) Immuno-oncolytic therapies
HK40045119B (en) Immuno-oncolytic therapies
HK40045119A (en) Immuno-oncolytic therapies
HK1223402B (zh) 免疫溶瘤療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160418

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190719

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190719

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190730

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190829

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190903

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190927

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191101

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191112

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200728

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210128

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210511

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210615

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210708

R150 Certificate of patent or registration of utility model

Ref document number: 6912199

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250